Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, drawn from the whole corpus: 7 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Whether temozolomide can replace PCV without losing survival (CODEL).
How to sequence vorasidenib, chemotherapy and radiotherapy over a disease course of decades.
Late cognitive effects of radiotherapy in long survivors.
No effective treatment for the rare tumours that acquire CDKN2A/B loss or hypermutation.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 16 changes by month →When this page itself was last checked or edited.
Grade 2 IDH-mutant astrocytoma or oligodendroglioma after surgery, age ≥12 (INDIGO): first targeted therapy for low-grade glioma
Grade 2 IDH-mutant astrocytoma or oligodendroglioma after surgery, age ≥12
A milestone in how this cancer is treated.
PFS 27.
A milestone in how this cancer is treated.